Abstract
The interindividual variability in drug response is a major issue in clinical practice and in drug development. Sulfoconjugation is an important Phase II reaction catalyzed by cytosolic sulfotransferases (SULTs), playing a major role in homeostatic functions, xenobiotic detoxification, and carcinogen bioactivation. SULT display wide interindividual variability, explained only partially by genetic variation, suggesting that other non-genetic, epigenetic, and environmental influences could be major determinants of variability in SULT activity. This review focuses on the factors known to influence SULT variability in expression and activity and the available evidence regarding the impact of SULT variability on drug response. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
| Original language | English |
|---|---|
| Pages (from-to) | 357-371 |
| Number of pages | 15 |
| Journal | Drug Metabolism Reviews |
| Volume | 49 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 2017 |
Keywords
- metabolic phenotype
- Phase II reactions
- Precision medicine
- sulfoconjugation
- SULT
- cell nucleus receptor
- dexamethasone
- ethinylestradiol
- nevirapine
- sulfotransferase
- sulfotransferase 1A1
- sulfotransferase 1A3
- sulfotransferase 1B1
- sulfotransferase 1C
- sulfotransferase 1E1
- sulfotransferase 2A1
- sulfotransferase 2B1
- sulfotransferase inhibitor
- tamoxifen
- tolvaptan
- troglitazone
- unclassified drug
- aging
- cytotoxicity
- drug efficacy
- drug metabolism
- drug response
- drug safety
- drug use
- enzyme activity
- enzyme structure
- gene expression
- genetic variation
- human
- inflammation
- liver disease
- liver injury
- liver toxicity
- pharmacogenetics
- phase 1 clinical trial (topic)
- phase 2 clinical trial (topic)
- protein function
- rash
- Review
- sex difference
